Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C.
10.3350/kjhep.2008.14.1.36
- Author:
Kyoung Tae KIM
1
;
Sang Young HAN
;
Jong Han KIM
;
Hyun Ah YOON
;
Yang Hyun BAEK
;
Min Ji KIM
;
Sung Wook LEE
;
Jin Seok JANG
;
Jong Hun LEE
;
Myung Hwan ROH
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. syhan@dau.ac.kr
- Publication Type:Original Article ; English Abstract
- Keywords:
Peginterferon;
Ribavirin;
Hepatitis C
- MeSH:
Adult;
Antiviral Agents/administration & dosage/*therapeutic use;
Drug Therapy, Combination;
Female;
Genotype;
Hepatitis C, Chronic/*drug therapy/genetics;
Humans;
Interferon Alfa-2a/administration & dosage/*therapeutic use;
Male;
Middle Aged;
Polyethylene Glycols/administration & dosage/*therapeutic use;
Reverse Transcriptase Polymerase Chain Reaction;
Ribavirin/administration & dosage/*therapeutic use;
Treatment Outcome
- From:The Korean Journal of Hepatology
2008;14(1):36-45
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: The purpose of this study is to elucidate the efficacy and safety of combined peginterferon and ribavirin therapy in Korean patients with chronic HCV infection. METHODS: We retrospectively analyzed the clinical records of 84 patients. Thirty five patients with genotype 1 HCV infection were treated with peginterferon alpha-2a 180 microgram/week and ribavirin 1,000-1,200 mg/day for 48 weeks, and 49 patients with genotype non-1 were treated with peginterferon alpha-2a 180 microgram/week and ribavirin 800 mg/day for 24 weeks. RESULTS: An early virologic response was seen in 87.0% of patients with genotype 1 HCV. An end of treatment response (ETR) was seen in 82.6% and 97.6% of patients with genotype 1 and genotype non-1, respectively. An overall sustained virologic response (SVR) was seen in 53 patients (82.8%) of the 64 patients: in 16 (69.6%) of 23 patients with genotype 1 and in 37 (90.2%) of 41 patients with genotype non-1. An end of treatment biochemical response was seen in 58 patients (90.6%) [genotype 1, 20 patients (87.0%); genotype non-1, 38 patients (92.7%)], and a sustained biochemical response was achieved in 49 patients (76.6%) [genotype 1, 14 patients (60.9%); genotype non-1, 35 patients (85.4%)]. Independent factors affecting an SVR were HCV genotype and the baseline HCV RNA level. CONCLUSIONS: This study shows that a combination therapy of peginterferon and ribavirin is highly effective for chronic HCV infection, producing a high SVR and ETR.
